HLN Stock Analysis: Haleon | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 37.688m USD | 12M Return: 0.2% | US4055521003 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 191M
EPS Trend: -2.8%
Qual. Beats: 0
Rev. Trend: 81.6%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, United Kingdom, with operations across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Founded in 1715 and renamed from DRVW 2022 plc in February 2022, the company manufactures and sells a broad portfolio of over-the-counter health products across oral care, vitamins and supplements, respiratory relief, pain management, and digestive health. Its brand portfolio includes Sensodyne, Polident, Parodontax, and Biotene (oral health); Centrum, Emergen-C, and Caltrate (vitamins and supplements); Theraflu and Flonase (cold, flu, and allergy); Voltaren, Panadol, and Advil (pain relief); and TUMS, ENO, and Fenistil (digestive health and antihistamines).
The company has a collaboration agreement with Microsoft to scale digital, data, and AI capabilities across its operations in support of its win as one global strategy. As a large-cap player in the consumer healthcare segment, Haleon operates in a sector characterized by branded, mass-market health products sold primarily through retail and pharmacy channels without prescriptions, where brand recognition and shelf presence are key competitive advantages.
- Sensodyne and Centrum pricing power offsets volume softness
- US cold and flu demand drives Flonase and Advil sales
- Sterling weakness pressures translated revenue and margins
| Net Income: 1.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.62 > 1.0 |
| NWC/Revenue: -17.40% < 20% (prev -7.54%; Δ -9.85% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.39b > Net Income 1.62b |
| Net Debt (7.51b) to EBITDA (2.95b): 2.55 < 3 |
| Current Ratio: 0.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.46b) vs 12m ago -3.21% < -2% |
| Gross Margin: 65.54% > 18% (prev 64.51%; Δ 1.04% > 0.5%) |
| Asset Turnover: 34.76% > 50% (prev 25.83%; Δ 8.93% > 0%) |
| Interest Coverage Ratio: 8.19 > 6 (EBIT TTM 2.60b / Interest Expense TTM 317.1m) |
| A: -0.06 (Total Current Assets 4.27b - Total Current Liabilities 6.21b) / Total Assets 32.4b |
| B: 0.85 (Retained Earnings 27.5b / Total Assets 32.4b) |
| C: 0.08 (EBIT TTM 2.60b / Avg Total Assets 32.1b) |
| D: 1.01 (Book Value of Equity 16.3b / Total Liabilities 16.0b) |
| Altman-Z'' = 3.99 = AA |
| DSRI: 0.80 (Receivables 2.33b/2.14b, Revenue 11.2b/8.22b) |
| GMI: 0.98 (GM 64.51% / 65.54%) |
| AQI: 0.99 (AQ_t 0.81 / AQ_t-1 0.81) |
| SGI: 1.36 (Revenue 11.2b / 8.22b) |
| TATA: -0.02 (NI 1.62b - CFO 2.39b) / TA 32.4b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of November 06, 2026, the stock is trading at USD 9.15 with a total of 38,366,765 shares traded. Over the past week, the price has changed by +6.77%, over one month by +3.74%, over three months by -7.44% and over the past year by +0.24%.
Current recommended Stop Loss: 8.70 (which is 4.9% or 1.6 ATR below the current price).
Haleon has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold HLN.
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11.9 | 30.4% |
Market Cap GBP = 27.9b (37.7b USD * 0.7414 USD.GBP)
P/E Trailing = 17.4898
P/E Forward = 14.3266
P/S = 3.3795
P/B = 1.7292
P/EG = 1.9617
Revenue TTM = 11.2b GBP
EBIT TTM = 2.60b GBP
EBITDA TTM = 2.95b GBP
Long Term Debt = 7.66b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 1.95b GBP (from shortTermDebt, last quarter)
Debt = 8.34b GBP (from shortLongTermDebtTotal, last quarter) + Leases 133.0m
Net Debt = 7.51b GBP (calculated: Debt 8.34b - CCE 821.0m)
Enterprise Value = 35.5b GBP (27.9b + Debt 8.34b - CCE 821.0m)
Interest Coverage Ratio = 8.19 (Ebit TTM 2.60b / Interest Expense TTM 317.1m)
EV/FCF = 17.31x (Enterprise Value 35.5b / FCF TTM 2.05b)
FCF Yield = 5.78% (FCF TTM 2.05b / Enterprise Value 35.5b)
FCF Margin = 18.36% (FCF TTM 2.05b / Revenue TTM 11.2b)
Net Margin = 14.55% (Net Income TTM 1.62b / Revenue TTM 11.2b)
Gross Margin = 65.54% ((Revenue TTM 11.2b - Cost of Revenue TTM 3.85b) / Revenue TTM)
Gross Margin QoQ = 66.05% (prev 65.03%)
Tobins Q-Ratio = 1.09 (Enterprise Value 35.5b / Total Assets 32.4b)
Interest Expense / Debt = 3.80% (Interest Expense 317.1m / Debt 8.34b)
Taxrate = 23.28% (496.8m / 2.13b)
NOPAT = 1.99b (EBIT 2.60b * (1 - 23.28%))
Current Ratio = 0.69 (Total Current Assets 4.27b / Total Current Liabilities 6.21b)
Debt / Equity = 0.51 (Debt 8.34b / totalStockholderEquity, last quarter 16.3b)
Debt / EBITDA = 2.55 (Net Debt 7.51b / EBITDA 2.95b)
Debt / FCF = 3.67 (Net Debt 7.51b / FCF TTM 2.05b)
Total Stockholder Equity = 16.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.06% (Net Income 1.62b / Total Assets 32.4b)
RoE = 10.06% (Net Income TTM 1.62b / Total Stockholder Equity 16.1b)
RoCE = 10.91% (EBIT 2.60b / Capital Employed (Equity 16.1b + L.T.Debt 7.66b))
RoIC = 7.22% (NOPAT 1.99b / Invested Capital 27.6b)
WACC = 4.34% (E(27.9b)/V(36.3b) * Re(4.76%) + D(8.34b)/V(36.3b) * Rd(3.80%) * (1-Tc(0.23)))
Discount Rate = 4.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.32 | Cagr: -1.53%
[DCF] Terminal Value 77.97% ; FCFF base≈1.83b ; Y1≈2.10b ; Y5≈3.09b
[DCF] Fair Price = 8.85 (EV 46.4b - Net Debt 7.51b = Equity 38.9b / Shares 4.40b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -2.77 | EPS CAGR: -4.90% | SUE: -0.22 | # QB: 0
Revenue Correlation: 81.58 | Revenue CAGR: 13.80% | SUE: 1.56 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.56 | Chg30d=-0.88% | Revisions=-40% | GrowthEPS=+11.0% | GrowthRev=+2.5%
EPS next Year (2027-12-31): EPS=0.62 | Chg30d=-1.07% | Revisions=-40% | GrowthEPS=+9.3% | GrowthRev=+4.2%
[Analyst] Revisions Ratio: -57% (up=0, down=4)